Cardiac electrophysiological and antiarrhythmic effects of N-n-butyl haloperidol iodide

Cellular Physiology and Biochemistry

Volumn 25, Issue 4-5, 2010, Pages 433-442

  Gao, Fen Fei ^a   Hao, Si Yuan ^b   Huang, Zhan Qin ^a   Zhang, Yan Mei ^a   Zhou, Yan Qiong ^a   Chen, Yi Cun ^a   Liu, Xing Ping ^a   Shi, Gang Gang ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b First Affiliated Hospital   (China)

Author keywords

Arrhythmia; Electrophysiology; Ionic currents; N n butyl haloperidol; Ventricular myocytes

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL L TYPE; N BUTYL HALOPERIDOL IODIDE; POTASSIUM ION; QUATERNARY AMMONIUM DERIVATIVE; SODIUM CHANNEL; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART ATRIOVENTRICULAR NODE; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE ARRHYTHMIA; IC 50; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SODIUM CURRENT; WENCKEBACH PERIOD;

RATTUS;

EID: 77949994816     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000303048     Document Type: Article

References (24)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
2. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
3. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12.
4. Shi GG, Zheng JH, Li CC, Chen JX, Zhuang XX, Chen SG, Liu XP: The effect of quaternary ammonium salt derivation of haloperidol on coromary artery. Chin Pharm J 1998;33:529-531 (Chinese).
5. Huang ZQ, Shi GG, Zheng JH, Liu B: Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and L-type calcium current. Acta Pharmacol Sin 2003;24:757-763.
6. Gao FF, Shi GG, Zheng JH, Liu B: Protective effects of N-n-butyl haloperidol iodide on myocardial ischemia-reperfusion injury in rabbits. Chin J Physiol 2004;47:61-66.
7. Huang ZQ, Shi GG, Gao FF, Zhang YM, Liu XP, Christopher TA, Lopez B, Ma XL: Effects of N-n-butyl haloperidol iodide on L-type calcium channels and intracellular free calcium in rat ventricular myocytes. Biochem Cell Biol 2007;85:182-188.
8. Zhang Y, Shi G, Zheng J, Tang Z, Gao P, Lv Y, Guo F, Jia Q: The protective effects of N-n-butyl haloperidol iodide on myocardial ischemia-reperfusion injury in rats by inhibiting Egr-1 overexpression. Cell Physiol Biochem 2007;20:639-648.
9. Chang GJ, Su MJ, Hung LM, Lee SS: Cardiac electrophysiologic and antiarrhythmic actions of a pavine alkaloid derivative, O-methyl-neocaryachine, in rat heart. Br J Pharmacol 2002;136:459-471.
10. Rees SA, Curtis MJ: Specific IK1 blockade: a new antiarrhythmic mechanism? Effect of RP58866 on ventricular arrhythmias in rat, rabbit, and primate. Circulation 1993;87:1979-1989.
11. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW, et al.: The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 1988;22:447-455.
12. Gao FF, Shi GG, Zhou YQ, Liu XP: Reformative cannula electrodes for His bundle electrogram recording in isolated rat hearts. Chin J Physiol 2008;51:116-119.
13. Delgado C, Tamargo J, Henzel D, Lorente P: Effects of propafenone on calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 1993;108:721-727.
14. Bebarova M, Matejovic P, Pasek M, Novakova M: Effect of haloperidol on transient outward potassium current in rat ventricular myocytes. Eur J Pharmacol 2006;550:15-23.
15. Corr PB, Witkowski FX: Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium. Circulation 1983;68:I16-24.
16. Bernier M, Curtis MJ, Hearse DJ: Ischemia-induced and reperfusion-induced arrhythmias: importance of heart rate. Am J Physiol 1989;256:H21-31.
17. Harrison DC: Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol 1985;56:185-187.
18. Hondeghem LM, Katzung BG: Time-and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 1977;472:373-398.
19. Hille B: Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497-515.
20. Bean BP, Cohen CJ, Tsien RW: Lidocaine block of cardiac sodium channels. J Gen Physiol 1983;81:613-642.
21. Hondeghem LM, Katzung BG: Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol 1984;24:387-423.
22. Yatani A, Brown AM, Schwartz A: Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther 1986;237:9-17.
23. Penkoske PA, Sobel BE, Corr PB: Disparate electrophysiological alterations accompanying dysrhythmia due to coronary occlusion and reperfusion in the cat. Circulation 1978;58:1023-1035.
24. Yong SL, Xu R, McLarnon JG, Zolotoy AB, Beatch GN, Walker MJ: RSD1000: a novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions. J Pharmacol Exp Ther 1999;289:236-244.